J. Sabari

N. Narula, C. Rockman, J. Sabari, 2021, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance

S. Devlin, A. Lesokhin, A. Dogan, 2017, Leukemia & lymphoma.

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.

P. Jänne, R. Heist, J. Christensen, 2022, The New England journal of medicine.

A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors

L. Dirix, R. Carvajal, M. Peeters, 2021, Investigational New Drugs.

Unravelling the biology of SCLC: implications for therapy

C. Rudin, J. Poirier, B. Lok, 2017, Nature Reviews Clinical Oncology.

Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes

L. Borsu, M. Ladanyi, A. Drilon, 2021, Clinical Cancer Research.

Clinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry

A. Drilon, M. Okada, S. Ou, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.

A. Drilon, C. Rudin, M. Kris, 2019, European journal of cancer.

Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.

M. Ladanyi, A. Drilon, C. Rudin, 2018, Cancer discovery.

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers

A. Drilon, C. Rudin, M. Kris, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Relevance of genetic alterations in squamous and small cell lung cancer.

P. Paik, J. Sabari, 2017, Annals of translational medicine.

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.

M. Ladanyi, C. Sima, M. Kris, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC

E. Cho, J. Infante, B. Cho, 2020 .

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.

S. Ou, Keunchil Park, E. Cho, 2021 .

Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications.

B. Cho, A. Spira, S. Vijayaraghavan, 2022, Clinical lung cancer.

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer

A. Giobbie-Hurder, S. Digumarthy, H. Wakimoto, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)

P. Jänne, S. Ou, J. Christensen, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy

A. Drilon, W. Lai, F. Santini, 2017, Current Oncology Reports.

KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation.

J. Christensen, Melissa L. Johnson, R. Yaeger, 2022, Journal of Clinical Oncology.

Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: Napsin A expression and genomic alterations

M. Ladanyi, C. Rudin, W. Travis, 2017, Modern Pathology.

Targeting RET-rearranged lung cancers with multikinase inhibitors

A. Drilon, J. Sabari, E. Siau, 2017, Oncoscience.

99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation

P. Jänne, S. Ou, R. Heist, 2021 .

KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.

Xiaohong Yan, P. Jänne, A. Tolcher, 2021 .

A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.

David R. Jones, L. Borsu, M. Ladanyi, 2018, Journal of the National Cancer Institute.

Outcomes of advanced pulmonary large cell neuroendocrine carcinoma stratified by RB1 loss, SLFN11 expression, and tumor mutational burden.

A. Drilon, C. Rudin, N. Rekhtman, 2018 .

Comparison of solid tissue sequencing and liquid biopsy accuracy in identification of clinically relevant gene mutations and rearrangements in lung adenocarcinomas

A. Moreira, M. Snuderl, V. Velcheti, 2021, Modern Pathology.

A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC.

A. Drilon, I. Lowy, S. Gadgeel, 2022, Journal of Clinical Oncology.

Have adjuvant tyrosine kinase inhibitors lost their shine?

J. Chaft, J. Sabari, 2016, Annals of translational medicine.

Extended Survival in Patients With Non–Small-Cell Lung Cancer–Associated Brain Metastases in the Modern Era

D. Kondziolka, J. Golfinos, V. Velcheti, 2023, Neurosurgery.

OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer

N. Girard, Dohoung Kim, B. Cho, 2021 .

Fibronectin Matrix Assembly Suppresses Dispersal of Glioblastoma Cells

Daniel Connors, R. Foty, I. Entersz, 2011, PloS one.

Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC.

Gregory Riely, D. Planchard, M. Hellmann, 2018 .

Dynamic Management of Lung Cancer Care During Surging COVID-19

R. Cerfolio, T. Geraci, J. Sabari, 2021, Frontiers in Surgery.

JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).

R. Govindan, Keunchil Park, E. Cho, 2019, Journal of Clinical Oncology.

Adagrasib in Non-Small-Cell Lung Cancer. Reply.

P. Jänne, A. Spira, J. Sabari, 2022, The New England journal of medicine.

PD-L1 expression, tumor mutation burden and response to immune checkpoint blockade in patients with HER2-mutant lung cancers.

A. Drilon, M. Kris, M. Arcila, 2018 .

The Selective Personalized Radio-immunotherapy for Locally Advanced NSCLC Trial (SPRINT): Initial results.

S. Jolly, B. Halmos, S. Gadgeel, 2022, Journal of Clinical Oncology.

Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).

N. Girard, Keunchil Park, Dong-Wan Kim, 2020 .

Afatinib in patients with metastatic HER2-mutant lung cancers: An international multicenter study.

C. Rudin, M. Kris, N. Pavlakis, 2017 .

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

P. Jänne, S. Ou, R. Heist, 2020 .

KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation.

S. Ou, R. Heist, J. Christensen, 2022, Journal of Clinical Oncology.

35P Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)

M. Hochmair, A. Spira, A. Panaccione, 2022, Annals of Oncology.

Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation

R. Yaeger, T. Bekaii-Saab, A. Spira, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer

M. Ladanyi, R. Shen, Gregory Riely, 2023, JCO precision oncology.

Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS.

T. Jatkoe, S. Ou, E. Felip, 2023, Journal of Clinical Oncology.

1018P Phase I/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients

F. Hirsch, R. Samstein, T. Marron, 2022, Annals of Oncology.

PS01.24: Clinical Outcomes of Patients with Pulmonary Large Cell Neuroendocrine Carcinoma Characterized by Next‐Generation Sequencing: Topic: Medical Oncology

C. Rudin, N. Rekhtman, J. Sabari, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry

A. Drilon, H. Wakelee, S. Ou, 2018, Journal of Thoracic Oncology.

Seeing Beyond the Smoke: Reclassifying Lung Cancer by Smoking-Related Mutational Signatures.

A. Moreira, J. Sabari, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors

T. Burns, R. Heist, Y. Murciano-Goroff, 2023, Cancer Research.

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases

P. Jänne, R. Heist, J. Christensen, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immune-Mediated Pneumonitis: A Clinical Conundrum in a Patient with Stage IV Lung Adenocarcinoma with a Dramatic and Durable Response to Checkpoint Inhibitor Case Report

J. Sabari, Ezra Bernstein, 2022, Current Problems in Cancer: Case Reports.

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

S. Ou, Keunchil Park, Dong-Wan Kim, 2023, Nature Medicine.

Selective Personalized RadioImmunotherapy for Locally Advanced Non–Small-Cell Lung Cancer Trial (SPRINT)

S. Jolly, B. Halmos, S. Gadgeel, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MO4-1 Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study

R. Govindan, Keunchil Park, R. Salgia, 2022, Annals of Oncology.